 Nalu Navarro Alvarez
Concepts (318)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 13 | 2023 | 695 | 2.600 |
Why?
| | Hepatocytes | 22 | 2016 | 195 | 2.590 |
Why?
| | Transplantation, Heterologous | 13 | 2020 | 180 | 2.320 |
Why?
| | Acute-On-Chronic Liver Failure | 4 | 2023 | 7 | 1.990 |
Why?
| | Liver Diseases | 7 | 2022 | 254 | 1.740 |
Why?
| | Liver Regeneration | 7 | 2022 | 29 | 1.440 |
Why?
| | Liver Failure | 5 | 2018 | 73 | 1.200 |
Why?
| | Graft Rejection | 5 | 2020 | 511 | 1.180 |
Why?
| | Swine | 15 | 2018 | 687 | 1.060 |
Why?
| | Embryonic Stem Cells | 8 | 2009 | 106 | 0.990 |
Why?
| | Galectins | 2 | 2022 | 22 | 0.980 |
Why?
| | Galectin 3 | 3 | 2022 | 18 | 0.930 |
Why?
| | CD47 Antigen | 3 | 2016 | 21 | 0.920 |
Why?
| | Blood Coagulation Factors | 5 | 2020 | 43 | 0.880 |
Why?
| | Papio | 6 | 2018 | 96 | 0.870 |
Why?
| | Heterografts | 2 | 2020 | 117 | 0.800 |
Why?
| | Hepatitis, Alcoholic | 1 | 2022 | 13 | 0.800 |
Why?
| | Cell Culture Techniques | 9 | 2009 | 341 | 0.750 |
Why?
| | Tissue Engineering | 8 | 2022 | 364 | 0.740 |
Why?
| | Graft Survival | 8 | 2020 | 443 | 0.730 |
Why?
| | Blood Component Removal | 2 | 2018 | 26 | 0.720 |
Why?
| | Liver | 13 | 2022 | 1633 | 0.630 |
Why?
| | Models, Animal | 3 | 2020 | 340 | 0.630 |
Why?
| | Islets of Langerhans Transplantation | 4 | 2008 | 52 | 0.610 |
Why?
| | Liver Cirrhosis | 5 | 2023 | 227 | 0.600 |
Why?
| | Betacoronavirus | 1 | 2020 | 247 | 0.570 |
Why?
| | Animals | 50 | 2022 | 31565 | 0.540 |
Why?
| | Bone Marrow Transplantation | 2 | 2015 | 237 | 0.530 |
Why?
| | Antigens, Heterophile | 1 | 2015 | 4 | 0.510 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 334 | 0.500 |
Why?
| | Coronavirus Infections | 1 | 2020 | 326 | 0.490 |
Why?
| | Inflammation | 3 | 2022 | 2464 | 0.480 |
Why?
| | Thrombocytopenia | 2 | 2016 | 177 | 0.480 |
Why?
| | Immunity, Humoral | 1 | 2015 | 112 | 0.470 |
Why?
| | Prognosis | 4 | 2022 | 3315 | 0.460 |
Why?
| | Stem Cells | 4 | 2016 | 541 | 0.460 |
Why?
| | Peptides | 3 | 2010 | 847 | 0.430 |
Why?
| | Gene Deletion | 2 | 2013 | 356 | 0.430 |
Why?
| | Islets of Langerhans | 5 | 2008 | 728 | 0.420 |
Why?
| | Swine, Miniature | 3 | 2018 | 70 | 0.420 |
Why?
| | Pandemics | 1 | 2020 | 1310 | 0.400 |
Why?
| | Cell Differentiation | 11 | 2010 | 1696 | 0.390 |
Why?
| | Hemorrhage | 1 | 2016 | 600 | 0.390 |
Why?
| | Liver Failure, Acute | 6 | 2015 | 58 | 0.380 |
Why?
| | Bone Marrow Cells | 2 | 2010 | 266 | 0.380 |
Why?
| | Hepatectomy | 6 | 2018 | 118 | 0.370 |
Why?
| | Biomarkers | 6 | 2022 | 3397 | 0.360 |
Why?
| | B-Lymphocytes | 1 | 2015 | 762 | 0.350 |
Why?
| | Blood Proteins | 2 | 2022 | 222 | 0.340 |
Why?
| | Animals, Genetically Modified | 4 | 2018 | 215 | 0.330 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2008 | 160 | 0.330 |
Why?
| | Tissue Scaffolds | 2 | 2009 | 179 | 0.320 |
Why?
| | Cell Separation | 1 | 2010 | 290 | 0.320 |
Why?
| | Phagocytosis | 1 | 2011 | 349 | 0.320 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 280 | 0.310 |
Why?
| | Glycoproteins | 1 | 2010 | 304 | 0.310 |
Why?
| | Humans | 43 | 2023 | 114045 | 0.310 |
Why?
| | Colonic Neoplasms | 1 | 2010 | 212 | 0.300 |
Why?
| | Antigens, CD | 1 | 2010 | 440 | 0.290 |
Why?
| | Fibronectins | 1 | 2008 | 108 | 0.280 |
Why?
| | Cell Transplantation | 4 | 2010 | 35 | 0.280 |
Why?
| | Pluripotent Stem Cells | 1 | 2008 | 64 | 0.280 |
Why?
| | Cytokines | 3 | 2022 | 1824 | 0.280 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2022 | 68 | 0.280 |
Why?
| | Mice | 23 | 2016 | 14843 | 0.270 |
Why?
| | Fibroblast Growth Factor 2 | 6 | 2009 | 82 | 0.250 |
Why?
| | Liver, Artificial | 4 | 2010 | 5 | 0.250 |
Why?
| | Transplantation, Heterotopic | 2 | 2018 | 16 | 0.240 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 2700 | 0.230 |
Why?
| | Mice, SCID | 8 | 2010 | 312 | 0.230 |
Why?
| | Hepatocyte Growth Factor | 5 | 2008 | 32 | 0.230 |
Why?
| | Patient Acuity | 1 | 2022 | 42 | 0.190 |
Why?
| | Pancreas, Artificial | 3 | 2009 | 68 | 0.190 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 94 | 0.190 |
Why?
| | Liver Function Tests | 2 | 2020 | 103 | 0.190 |
Why?
| | Gastroenterology | 1 | 2023 | 159 | 0.180 |
Why?
| | Stem Cell Transplantation | 4 | 2009 | 148 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2022 | 475 | 0.180 |
Why?
| | Consensus | 1 | 2023 | 532 | 0.180 |
Why?
| | Postoperative Complications | 3 | 2022 | 2122 | 0.170 |
Why?
| | Choledocholithiasis | 1 | 2020 | 14 | 0.170 |
Why?
| | Gallstones | 1 | 2020 | 28 | 0.170 |
Why?
| | Lithotripsy | 1 | 2020 | 40 | 0.170 |
Why?
| | Retrospective Studies | 5 | 2022 | 12521 | 0.170 |
Why?
| | End Stage Liver Disease | 1 | 2020 | 61 | 0.170 |
Why?
| | Brain Diseases | 1 | 2020 | 124 | 0.160 |
Why?
| | Risk | 1 | 2022 | 810 | 0.160 |
Why?
| | Galactosyltransferases | 1 | 2018 | 11 | 0.160 |
Why?
| | Primates | 1 | 2020 | 110 | 0.160 |
Why?
| | Renal Insufficiency | 1 | 2020 | 137 | 0.160 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 98 | 0.150 |
Why?
| | Freund's Adjuvant | 1 | 2018 | 17 | 0.150 |
Why?
| | Postoperative Care | 1 | 2020 | 223 | 0.150 |
Why?
| | Cell Line | 6 | 2010 | 2629 | 0.150 |
Why?
| | Lithiasis | 1 | 2017 | 3 | 0.150 |
Why?
| | Aftercare | 1 | 2020 | 186 | 0.150 |
Why?
| | Preoperative Care | 1 | 2020 | 319 | 0.140 |
Why?
| | Neovascularization, Physiologic | 3 | 2009 | 174 | 0.140 |
Why?
| | Cells, Cultured | 6 | 2013 | 3861 | 0.140 |
Why?
| | Ammonia | 6 | 2007 | 56 | 0.140 |
Why?
| | Disease Models, Animal | 4 | 2018 | 3498 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 1791 | 0.140 |
Why?
| | Mycoplasma ovipneumoniae | 1 | 2016 | 1 | 0.140 |
Why?
| | Peptide Elongation Factor Tu | 1 | 2016 | 5 | 0.140 |
Why?
| | Endoscopy, Digestive System | 1 | 2017 | 110 | 0.130 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2016 | 30 | 0.130 |
Why?
| | Lymphocyte Depletion | 1 | 2016 | 115 | 0.130 |
Why?
| | Treatment Outcome | 7 | 2020 | 9049 | 0.130 |
Why?
| | Transplantation Tolerance | 1 | 2016 | 30 | 0.130 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2016 | 61 | 0.130 |
Why?
| | Immunosuppressive Agents | 2 | 2017 | 641 | 0.130 |
Why?
| | Microscopy, Electron, Transmission | 4 | 2009 | 134 | 0.130 |
Why?
| | Antibodies, Heterophile | 1 | 2015 | 13 | 0.130 |
Why?
| | Lidocaine | 5 | 2006 | 40 | 0.130 |
Why?
| | Neoplastic Stem Cells | 2 | 2010 | 327 | 0.130 |
Why?
| | Albumins | 5 | 2007 | 89 | 0.120 |
Why?
| | Health Status Indicators | 1 | 2016 | 155 | 0.120 |
Why?
| | alpha-Fetoproteins | 1 | 2015 | 31 | 0.120 |
Why?
| | Activins | 4 | 2008 | 26 | 0.120 |
Why?
| | Female | 14 | 2022 | 59324 | 0.120 |
Why?
| | Oligopeptides | 2 | 2007 | 234 | 0.120 |
Why?
| | Severity of Illness Index | 1 | 2022 | 2537 | 0.120 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2008 | 3254 | 0.110 |
Why?
| | Mice, Inbred BALB C | 7 | 2016 | 1144 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 337 | 0.110 |
Why?
| | Exosomes | 1 | 2015 | 92 | 0.110 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 74 | 0.110 |
Why?
| | Skin | 1 | 2018 | 653 | 0.110 |
Why?
| | Immune Tolerance | 1 | 2015 | 321 | 0.110 |
Why?
| | Coculture Techniques | 3 | 2010 | 198 | 0.110 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2015 | 210 | 0.110 |
Why?
| | Nanofibers | 2 | 2010 | 19 | 0.110 |
Why?
| | Macrophage-1 Antigen | 1 | 2013 | 25 | 0.110 |
Why?
| | Cell Proliferation | 3 | 2010 | 2173 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2016 | 336 | 0.100 |
Why?
| | Apoptosis | 4 | 2010 | 2349 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2013 | 126 | 0.100 |
Why?
| | Time Factors | 4 | 2010 | 6077 | 0.090 |
Why?
| | Gelatin | 2 | 2009 | 36 | 0.090 |
Why?
| | Microscopy, Electron, Scanning | 3 | 2006 | 192 | 0.090 |
Why?
| | Male | 11 | 2022 | 55396 | 0.090 |
Why?
| | Adult | 5 | 2022 | 30375 | 0.090 |
Why?
| | Embryonic Induction | 2 | 2008 | 30 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2015 | 720 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2010 | 347 | 0.090 |
Why?
| | Liver Neoplasms | 1 | 2015 | 504 | 0.090 |
Why?
| | Prospective Studies | 1 | 2022 | 6195 | 0.090 |
Why?
| | Insulin | 4 | 2008 | 2080 | 0.090 |
Why?
| | Mice, Inbred C57BL | 3 | 2016 | 4680 | 0.090 |
Why?
| | AC133 Antigen | 1 | 2010 | 19 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2010 | 73 | 0.090 |
Why?
| | Stromal Cells | 1 | 2010 | 96 | 0.090 |
Why?
| | Alkaline Phosphatase | 2 | 2008 | 142 | 0.090 |
Why?
| | Polytetrafluoroethylene | 2 | 2007 | 25 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2015 | 453 | 0.080 |
Why?
| | Cell Line, Transformed | 2 | 2007 | 133 | 0.080 |
Why?
| | Middle Aged | 5 | 2022 | 26605 | 0.080 |
Why?
| | Organoids | 1 | 2010 | 74 | 0.080 |
Why?
| | Injections, Intramuscular | 1 | 2009 | 117 | 0.080 |
Why?
| | MicroRNAs | 1 | 2015 | 600 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2009 | 56 | 0.080 |
Why?
| | Nanotechnology | 1 | 2009 | 113 | 0.080 |
Why?
| | Gene Expression Profiling | 3 | 2010 | 1518 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1735 | 0.080 |
Why?
| | Abdomen | 1 | 2009 | 99 | 0.080 |
Why?
| | Endoderm | 1 | 2008 | 19 | 0.080 |
Why?
| | Drug Discovery | 1 | 2009 | 123 | 0.080 |
Why?
| | Nanog Homeobox Protein | 1 | 2008 | 11 | 0.070 |
Why?
| | Culture Media, Serum-Free | 1 | 2008 | 42 | 0.070 |
Why?
| | Octamer Transcription Factor-3 | 1 | 2008 | 16 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2010 | 695 | 0.070 |
Why?
| | Japan | 1 | 2008 | 85 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1947 | 0.070 |
Why?
| | Phenotype | 3 | 2010 | 2784 | 0.070 |
Why?
| | Survival Rate | 3 | 2020 | 1638 | 0.070 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 103 | 0.070 |
Why?
| | Organ Preservation | 1 | 2008 | 64 | 0.070 |
Why?
| | Rats | 5 | 2017 | 4913 | 0.070 |
Why?
| | Survival Analysis | 4 | 2016 | 1206 | 0.070 |
Why?
| | Polyurethanes | 1 | 2007 | 34 | 0.070 |
Why?
| | Bioartificial Organs | 1 | 2006 | 3 | 0.070 |
Why?
| | Fibroblast Growth Factors | 1 | 2008 | 162 | 0.070 |
Why?
| | Aged | 2 | 2022 | 18969 | 0.070 |
Why?
| | Membranes, Artificial | 1 | 2006 | 64 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2008 | 1003 | 0.060 |
Why?
| | Genetic Enhancement | 1 | 2005 | 6 | 0.060 |
Why?
| | Bone Regeneration | 1 | 2006 | 21 | 0.060 |
Why?
| | Pancreas | 1 | 2008 | 276 | 0.060 |
Why?
| | Bone Substitutes | 1 | 2006 | 27 | 0.060 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 386 | 0.060 |
Why?
| | Glucose | 2 | 2008 | 899 | 0.060 |
Why?
| | Totipotent Stem Cells | 1 | 2005 | 1 | 0.060 |
Why?
| | Delayed-Action Preparations | 1 | 2006 | 158 | 0.060 |
Why?
| | Bone Transplantation | 1 | 2006 | 97 | 0.060 |
Why?
| | Skull | 1 | 2006 | 119 | 0.060 |
Why?
| | Nanostructures | 1 | 2006 | 94 | 0.060 |
Why?
| | Homeodomain Proteins | 1 | 2008 | 465 | 0.060 |
Why?
| | Biomarkers, Tumor | 1 | 2010 | 1032 | 0.060 |
Why?
| | Gene Transfer Techniques | 1 | 2005 | 147 | 0.060 |
Why?
| | Pregnancy | 1 | 2015 | 5499 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2008 | 665 | 0.060 |
Why?
| | Collagen | 1 | 2006 | 414 | 0.050 |
Why?
| | Mexico | 1 | 2023 | 162 | 0.050 |
Why?
| | Immunoglobulin G | 2 | 2017 | 766 | 0.050 |
Why?
| | Knowledge | 1 | 2022 | 48 | 0.050 |
Why?
| | Hyperplasia | 1 | 2022 | 163 | 0.050 |
Why?
| | Extracellular Matrix | 1 | 2006 | 436 | 0.050 |
Why?
| | Diazepam | 3 | 2007 | 26 | 0.050 |
Why?
| | Diabetes Mellitus | 2 | 2008 | 898 | 0.050 |
Why?
| | Fibroblasts | 1 | 2006 | 834 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2006 | 677 | 0.040 |
Why?
| | Muscle, Skeletal | 1 | 2009 | 1468 | 0.040 |
Why?
| | Cell Survival | 3 | 2010 | 1014 | 0.040 |
Why?
| | Sus scrofa | 2 | 2010 | 45 | 0.040 |
Why?
| | Adult Stem Cells | 2 | 2008 | 32 | 0.040 |
Why?
| | Endoscopy | 1 | 2020 | 245 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 1078 | 0.040 |
Why?
| | Gene Expression | 3 | 2008 | 1417 | 0.040 |
Why?
| | Antibody Affinity | 1 | 2017 | 51 | 0.030 |
Why?
| | Receptors, CCR4 | 1 | 2016 | 15 | 0.030 |
Why?
| | Immunotoxins | 1 | 2016 | 33 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 175 | 0.030 |
Why?
| | Diphtheria Toxin | 1 | 2016 | 51 | 0.030 |
Why?
| | Interleukin-5 | 1 | 2016 | 30 | 0.030 |
Why?
| | Cross Reactions | 1 | 2016 | 118 | 0.030 |
Why?
| | Critical Care | 1 | 2020 | 472 | 0.030 |
Why?
| | Spleen | 2 | 2010 | 485 | 0.030 |
Why?
| | Endothelial Progenitor Cells | 1 | 2016 | 18 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 924 | 0.030 |
Why?
| | Interleukin-12 | 1 | 2016 | 110 | 0.030 |
Why?
| | Skin Transplantation | 1 | 2016 | 57 | 0.030 |
Why?
| | Blood Vessels | 2 | 2009 | 179 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2016 | 204 | 0.030 |
Why?
| | Reoperation | 1 | 2017 | 513 | 0.030 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2016 | 56 | 0.030 |
Why?
| | Diagnosis | 1 | 2015 | 9 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2016 | 247 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 787 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 241 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2086 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 813 | 0.030 |
Why?
| | Cell Division | 2 | 2006 | 754 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2017 | 1228 | 0.030 |
Why?
| | Actins | 2 | 2006 | 376 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 441 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 338 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2016 | 719 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2016 | 673 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2014 | 265 | 0.020 |
Why?
| | Hospitalization | 1 | 2020 | 1762 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2016 | 1128 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2016 | 1016 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1257 | 0.020 |
Why?
| | Bioengineering | 1 | 2010 | 13 | 0.020 |
Why?
| | Implants, Experimental | 1 | 2010 | 18 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 2562 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2010 | 2322 | 0.020 |
Why?
| | Endotoxemia | 1 | 2010 | 86 | 0.020 |
Why?
| | Rats, Inbred Lew | 1 | 2009 | 90 | 0.020 |
Why?
| | Glucocorticoid-Induced TNFR-Related Protein | 1 | 2008 | 5 | 0.020 |
Why?
| | Regeneration | 1 | 2010 | 158 | 0.020 |
Why?
| | Carbon Tetrachloride | 1 | 2008 | 6 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2008 | 408 | 0.020 |
Why?
| | Fetal Stem Cells | 1 | 2008 | 7 | 0.020 |
Why?
| | Biomedical Engineering | 1 | 2008 | 24 | 0.020 |
Why?
| | Cell Lineage | 1 | 2009 | 308 | 0.020 |
Why?
| | Hepatic Artery | 1 | 2008 | 49 | 0.020 |
Why?
| | Transcription Factors | 2 | 2006 | 1526 | 0.020 |
Why?
| | Regenerative Medicine | 1 | 2008 | 41 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 8614 | 0.020 |
Why?
| | Transplantation, Isogeneic | 1 | 2007 | 17 | 0.020 |
Why?
| | Portal Vein | 1 | 2008 | 75 | 0.020 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 12 | 0.020 |
Why?
| | Annexin A5 | 1 | 2007 | 22 | 0.020 |
Why?
| | Materials Testing | 1 | 2009 | 337 | 0.020 |
Why?
| | Blood Glucose | 2 | 2006 | 1827 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2010 | 813 | 0.020 |
Why?
| | Retroviridae | 1 | 2007 | 89 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2008 | 552 | 0.020 |
Why?
| | Dexamethasone | 1 | 2008 | 316 | 0.020 |
Why?
| | NF-kappa B | 1 | 2010 | 636 | 0.020 |
Why?
| | Integrases | 1 | 2007 | 116 | 0.020 |
Why?
| | Sp7 Transcription Factor | 1 | 2006 | 7 | 0.020 |
Why?
| | Tissue Survival | 1 | 2006 | 13 | 0.020 |
Why?
| | Tamoxifen | 1 | 2007 | 190 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 2007 | 176 | 0.020 |
Why?
| | Haplorhini | 1 | 2006 | 57 | 0.020 |
Why?
| | Ganciclovir | 1 | 2006 | 48 | 0.020 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2006 | 40 | 0.020 |
Why?
| | Glycogen | 1 | 2006 | 51 | 0.020 |
Why?
| | Urethane | 1 | 2006 | 41 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 211 | 0.020 |
Why?
| | Mitochondria, Liver | 1 | 2006 | 67 | 0.020 |
Why?
| | Polyamines | 1 | 2006 | 35 | 0.020 |
Why?
| | Textiles | 1 | 2006 | 19 | 0.020 |
Why?
| | Urea | 1 | 2006 | 66 | 0.020 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2005 | 13 | 0.020 |
Why?
| | Coated Materials, Biocompatible | 1 | 2006 | 54 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2182 | 0.020 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2005 | 14 | 0.020 |
Why?
| | Collagen Type I | 1 | 2006 | 108 | 0.020 |
Why?
| | Serum Albumin | 1 | 2006 | 137 | 0.020 |
Why?
| | Tissue Culture Techniques | 1 | 2005 | 66 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 213 | 0.020 |
Why?
| | Tissue Donors | 1 | 2007 | 314 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2006 | 343 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2006 | 426 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2005 | 287 | 0.010 |
Why?
| | Laparoscopy | 1 | 2008 | 395 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2005 | 293 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 1836 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1624 | 0.010 |
Why?
| | Genetic Variation | 1 | 2005 | 868 | 0.010 |
Why?
| | Models, Biological | 1 | 2006 | 1611 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2006 | 2550 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1311 | 0.010 |
Why?
| | Mutation | 1 | 2006 | 3338 | 0.010 |
Why?
| | Child | 1 | 2005 | 18401 | 0.000 |
Why?
|
|
Navarro Alvarez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|